"God's Drug" Redsewey Final Pricing Announcement! $390 per bottle fell short of Wall Street expectations.

In an open letter, Daniel O'Day, the company's chairman and chief executive, said That in order to ensure broad and fair access to drugs, Gilead had set the price of Redsiwe to developed governments at $390 a bottle, in a world where it was urgently needed.
, based on the current treatment model, the vast majority of patients are expected to receive five days of treatment, the treatment will use six bottles of Redsiwe, thus equivalent to the cost of a course of treatment per patient is $2,340, or about 165,000 yuan.
, the price for private insurance companies in the United States will be $520 per bottle, or about $3,120 a course of treatment, or about 22,000 yuan. How
set a $390 price tag? Redsiwe has been the focus of attention since the outbreak of the New Crown outbreak, and in addition to the efficacy, prices are also the focus of attention.
in the United States, two authorities, Wall Street and ICER, have given their own price forecasts or recommendations.
the report on drug pricing published by the American Institute of Clinical and Economic Review (ICER) has considerable influence in academia and industry and may have a direct impact on the market price of prescription drugs in the United States.
in its latest report last week, ICER found Redsewey to be cost-effective, with treatment costs between $4,580 and $5,080 per patient.
, icER believes that if the low-cost Dexametason is approved, Redsewe's price will be cut to $2,520 to $2,800 per course.
This month British researchers published data on dexamethasone clinical studies, suggesting that the drug could be an effective anti-neo-coronadrug.
on the other hand, Gilead's final price was also lower than Wall Street analysts had predicted.
$5,000 is a fair price backed by Wall Street analysts, and SVB Leerink, the US investment bank, recently estimated that Redsewe's sales could reach $1.9bn this year and peak at $7.6bn in 2022.
but other analysts say Redsewe won't generate much revenue in the short term, especially during the pandemic. Brian Abrahams, an analyst at RBC, an investment bank
, wrote in a report Monday that Gilead expects to sell 1.5 million courses of drugs by 2020, and that it could generate about $2.3 billion in revenue at a government price of $2,340.
notable, Gilead is expected to spend about $1 billion on the drug in 2020 alone.
but it is very important that if new coronal vaccines are developed globally, or other proven better treatments, Redsewe's growth space will also have to be affected.
a clinical trial of the drug sponsored by the National Institutes of Health (NIH) showed that about 1,000 patients admitted to hospital with new crowns could reduce their average length of stay by up to four days after receiving treatment, and Gilead said these early discharges would save the hospital about $12,000, so the current pricing would add value to the health system, even without taking into account the benefits to the patients themselves.
at the same time, Gilead says there is no precedent for current pricing, which is well below its value, and is "correct and responsible": the decision was made in part to eliminate the need for countries to negotiate prices.
we have reduced prices to levels that are affordable in the least purchasing countries.
this price will apply to all developed countries around the world that have approved or authorized the use of Redsewe.
for developing countries, Gilead said it had reached an agreement with generic drug makers to make them available at a lower price to ensure accessibility.
, Gilead Sciences has signed voluntary licensing agreements with nine generic drug manufacturers.
Hetero Labs and Cipla, two generic stakes, will offer generics at 5,000-6,000 rupees ($65-$78) and 3,000-4,000 rupees ($39-42) per 100 milligrams, respectively.
dispute is pending, but there is still a dispute over Redsewee's efficacy.
" did not speed up the recovery of COVID-19, nor did it reduce the fatality rate.
" the results of the world's first randomized, double-blind, placebo-controlled, multi-center clinical trial of the new coronapneumonia (COVID-19) antiviral drug Redsiwe, published online april 29 in the international medical journal The Lancet online.
" The trial found no significant benefits compared to placebos, although Redsewe was safe and well tolerated. Cao Bin, vice president of the China-Japan Friendship Hospital, which led the study
, said in an interview.
Professor John Norrie of the University of Edinburgh in the UK (not involved in the study) commented in a paper published in The Lancet at the same time: "This study is well-designed as a double-blind, placebo-controlled, multi-center randomized trial, well implemented, with high programme compliance and minimal absence of visits."
" But on April 29th, the U.S. and Chinese research teams published three clinical trial results from Redsewe, with differing conclusions.
U.S. researchers believe that Redsewe has a significant positive effect on shortening the recovery time.
Director of the National Institute of Allergy and Infectious Diseases (NIAID) said Redsewe showed efficacy in a randomized double-blind controlled trial at NIAID, which can moderate the recovery of patients infected with the new coronavirus.
day, Gilead also announced the results of an open-label phase III clinical trial that showed that patients who received a five-day course of treatment with Redsewe had a similar clinical improvement to those who received a 10-day Redsiwecourse course.
based on the positive conclusions of the U.S. study, on May 1, the FDA issued an Emergency Use Authorization (EUA) for the treatment of new coronary pneumonia for Redsewe, who is still in the study, to treat critical patients with suspected or confirmed new coronary pneumonia, including adults and children.
questioned the difference in conclusions between China and the United States in clinical trials, Cao Bin's view is that the evaluation criteria are different. John Norrie, a
, points out that although the Chinese experiment was well designed, it ended early and there was "insufficient support" for the results.
Gilead said Redsewe's approvals varied from country to country based on current public health emergencies and available clinical data.
in countries where local health agencies have not approved Redsiwe, Redsewe is still working on the drug, and its safety and efficacy are not yet clear.
but the company will continue to explore the possibility of helping in different ways in this outbreak, such as evaluating interventional treatment at an early stage of the disease, in outpatient settings, through inhalation agents, applications in more patient populations, and combination therapies with other drugs.
the controversy continues around the world, even though the FDA has now granted emergency use of the drug.
.